Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by s

Liu, Xiufen; Onda, Masanori; Watson, Nathan; Hassan, Raffit; Ho, Mitchell; Bera, Tapan K.; Wei, Junxia; Chakraborty, Anirban; Beers, Richard; Zhou, Qi; Shajahan, Asif; Azadi, Parastoo; Zhan, Jingyu; Xia, Di; Pastan, Ira

doi:10.1073/pnas.2202439119

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by s

Journal Article · 01 May 2022 · Proc. Natl. Acad. Sci. USA

DOI:https://doi.org/10.1073/pnas.2202439119· OSTI ID:1901060

Liu, Xiufen; Onda, Masanori; Watson, Nathan; Hassan, Raffit; Ho, Mitchell; Bera, Tapan K.; Wei, Junxia; Chakraborty, Anirban; Beers, Richard; Zhou, Qi; Shajahan, Asif; Azadi, Parastoo; Zhan, Jingyu; Xia, Di; Pastan, Ira

Research Organization:: Advanced Photon Source (APS), Argonne National Laboratory (ANL), Argonne, IL (US)

Sponsoring Organization:: DOE - Office Of Science; NIH

DOE Contract Number:: NONE;

OSTI ID:: 1901060

Journal Information:: Proc. Natl. Acad. Sci. USA, Journal Name: Proc. Natl. Acad. Sci. USA Journal Issue: (19) Vol. 119

Country of Publication:: United States

Language:: ENGLISH

References (32)

Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium Chang, Kai; Pastan, Ira; Willingham, Mark C. International Journal of Cancer, Vol. 50, Issue 3 https://doi.org/10.1002/ijc.2910500308	journal	February 1992
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing Li, Ji; Stagg, Nicola J.; Johnston, Jennifer Cancer Cell, Vol. 31, Issue 3 https://doi.org/10.1016/j.ccell.2017.02.001	journal	March 2017
CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice Li, Nan; Torres, Madeline B.; Spetz, Madeline R. Cell Reports Medicine, Vol. 2, Issue 6 https://doi.org/10.1016/j.xcrm.2021.100297	journal	June 2021
Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells Xiong, Wei; Chen, Yuhui; Kang, Xi Molecular Therapy, Vol. 26, Issue 4 https://doi.org/10.1016/j.ymthe.2018.01.020	journal	April 2018
Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor Zhang, Zhiwei; Jiang, Duqing; Yang, Huan Cell Death & Disease, Vol. 10, Issue 7 https://doi.org/10.1038/s41419-019-1711-1	journal	June 2019
Multiple proteases are involved in mesothelin shedding by cancer cells Liu, Xiufen; Chan, Alexander; Tai, Chin-Hsien Communications Biology, Vol. 3, Issue 1 https://doi.org/10.1038/s42003-020-01464-5	journal	December 2020
New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma Zhang, Yi-Fan; Phung, Yen; Gao, Wei Scientific Reports, Vol. 5, Issue 1 https://doi.org/10.1038/srep09928	journal	May 2015
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial Beatty, Gregory L.; O’Hara, Mark H.; Lacey, Simon F. Gastroenterology, Vol. 155, Issue 1 https://doi.org/10.1053/j.gastro.2018.03.029	journal	July 2018
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors Zhang, Yujian; Xiang, Laiman; Hassan, Raffit Proceedings of the National Academy of Sciences, Vol. 104, Issue 43 https://doi.org/10.1073/pnas.0708101104	journal	October 2007
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains Carpenito, Carmine; Milone, Michael C.; Hassan, Raffit Proceedings of the National Academy of Sciences, Vol. 106, Issue 9 https://doi.org/10.1073/pnas.0813101106	journal	March 2009
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Chang, K.; Pastan, I. Proceedings of the National Academy of Sciences, Vol. 93, Issue 1 https://doi.org/10.1073/pnas.93.1.136	journal	January 1996
Recognition of Mesothelin by the Therapeutic Antibody MORAb-009 Ma, Jichun; Tang, Wai Kwan; Esser, Lothar Journal of Biological Chemistry, Vol. 287, Issue 40 https://doi.org/10.1074/jbc.M112.381756	journal	September 2012
A Binding Domain on Mesothelin for CA125/MUC16 Kaneko, Osamu; Gong, Lucy; Zhang, Jingli Journal of Biological Chemistry, Vol. 284, Issue 6 https://doi.org/10.1074/jbc.M806776200	journal	February 2009
Mesothelin-targeted CAR-T cell therapy for solid tumors Klampatsa, Astero; Dimou, Vivian; Albelda, Steven M. Expert Opinion on Biological Therapy, Vol. 21, Issue 4 https://doi.org/10.1080/14712598.2021.1843628	journal	November 2020
A new anti-mesothelin antibody targets selectively the membrane-associated form Asgarov, Kamal; Balland, Jeremy; Tirole, Charline mAbs, Vol. 9, Issue 3 https://doi.org/10.1080/19420862.2017.1288770	journal	February 2017
Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors Hatterer, Eric; Chauchet, Xavier; Richard, Françoise mAbs, Vol. 12, Issue 1 https://doi.org/10.1080/19420862.2020.1739408	journal	January 2020
The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences Perez-Riverol, Yasset; Bai, Jingwen; Bandla, Chakradhar Nucleic Acids Research, Vol. 50, Issue D1 https://doi.org/10.1093/nar/gkab1038	journal	November 2021
Application of Mesothelin Immunostaining in Tumor Diagnosis Ordóñez, Nelson G. The American Journal of Surgical Pathology, Vol. 27, Issue 11 https://doi.org/10.1097/00000478-200311000-00003	journal	November 2003
dbSNP—Database for Single Nucleotide Polymorphisms and Other Classes of Minor Genetic Variation Sherry, Stephen T.; Ward, Minghong; Sirotkin, Karl Genome Research, Vol. 9, Issue 8 https://doi.org/10.1101/gr.9.8.677	journal	August 1999
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression Hassan, Raffit; Miller, Andrew C.; Sharon, Elad Science Translational Medicine, Vol. 5, Issue 208 https://doi.org/10.1126/scitranslmed.3006941	journal	October 2013
Cytotoxic Activity of Immunotoxin SS1P Is Modulated by TACE-Dependent Mesothelin Shedding Zhang, Yujian; Chertov, Oleg; Zhang, Jingli Cancer Research, Vol. 71, Issue 17 https://doi.org/10.1158/0008-5472.CAN-11-0466	journal	August 2011
New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA Onda, Masanori; Willingham, Mark; Nagata, Satoshi Clinical Cancer Research, Vol. 11, Issue 16 https://doi.org/10.1158/1078-0432.CCR-05-0578	journal	August 2005
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers Hassan, Raffit; Cohen, Steven J.; Phillips, Martin Clinical Cancer Research, Vol. 16, Issue 24 https://doi.org/10.1158/1078-0432.CCR-10-2275	journal	December 2010
Preclinical Characterization of HPN536, a Trispecific, T-Cell–Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors Molloy, Mary Ellen; Austin, Richard J.; Lemon, Bryan D. Clinical Cancer Research, Vol. 27, Issue 5 https://doi.org/10.1158/1078-0432.CCR-20-3392	journal	March 2021
Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins Awuah, Prince; Bera, Tapan K.; Folivi, Messan Molecular Cancer Therapeutics, Vol. 15, Issue 7 https://doi.org/10.1158/1535-7163.MCT-15-0863	journal	July 2016
Mesothelin Enhances Tumor Vascularity in Newly Forming Pancreatic Peritoneal Metastases Avula, Leela Rani; Rudloff, Michael; El-Behaedi, Salma Molecular Cancer Research, Vol. 18, Issue 2 https://doi.org/10.1158/1541-7786.MCR-19-0688	journal	February 2020
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors Morello, Aurore; Sadelain, Michel; Adusumilli, Prasad S. Cancer Discovery, Vol. 6, Issue 2 https://doi.org/10.1158/2159-8290.CD-15-0583	journal	February 2016
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab Adusumilli, Prasad S.; Zauderer, Marjorie G.; Rivière, Isabelle Cancer Discovery, Vol. 11, Issue 11 https://doi.org/10.1158/2159-8290.CD-21-0407	journal	July 2021
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia Haso, Waleed; Lee, Daniel W.; Shah, Nirali N. Blood, Vol. 121, Issue 7 https://doi.org/10.1182/blood-2012-06-438002	journal	February 2013
Mesothelin Immunotherapy for Cancer: Ready for Prime Time? Hassan, Raffit; Thomas, Anish; Alewine, Christine Journal of Clinical Oncology, Vol. 34, Issue 34 https://doi.org/10.1200/JCO.2016.68.3672	journal	December 2016
Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma Yeo, Dannel; Castelletti, Laura; van Zandwijk, Nico Cancers, Vol. 13, Issue 16 https://doi.org/10.3390/cancers13163932	journal	August 2021
Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms Cleary, Kirstie L. S.; Chan, H. T. Claude; James, Sonja The Journal of Immunology, Vol. 198, Issue 10 https://doi.org/10.4049/jimmunol.1601473	journal	April 2017

Similar Records

Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo

Journal Article · 2021 · Experimental Cell Research · OSTI ID:23195443

Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation

Journal Article · 2019 · Cell Reports · OSTI ID:1771822

Autoregulation by the Juxtamembrane Region of the Human Ephrin Receptor Tyrosine Kinase A3 (EphA3)

Journal Article · 2008 · Structure · OSTI ID:1006696

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by s

Citation Formats

References (32)

Similar Records

Related Subjects